Incyte’s Jakafi Gets Broad Label, Early Approval For Myelofibrosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Incyte Corp. hits the trifecta – a first-in-class, first-in-disease and first launch with the Nov. 16 FDA approval of Jakafi (ruxolitinib) for treatment of the progressive bone marrow cancer.
You may also be interested in...
Ahead Of Ryoncil’s Advisory Committee, Citizen Petition Opposes Approval For Pediatric GVHD
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Keeping Track: Accelerated Approval For Tecentriq And A Burst Of Filings And Submissions
The latest drug development news and highlights from our US FDA Performance Tracker.
CTI Lands Baxter As Pacritinib Partner To Try To Reach Finish Line
The beleaguered oncology company has inked a partnership for its third late-stage candidate with hopes of taking it through approval, unlike its last two attempts.